Cagrilintide acetate is a long-acting amylin analog designed to treat obesity by mimicking the effects of natural amylin and activating both amylin and calcitonin receptors. This dual mechanism reduces appetite and supports weight loss while also improving glucose regulation. Unlike earlier analogs, cagrilintide’s extended action allows it to suppress food intake for up to 72 hours post-injection. Clinical studies show it’s even more effective when combined with GLP-1 agonists like semaglutide, making it a strong candidate for addressing obesity and type 2 diabetes together.
Larsen, A.T., Mohamed, K.E., Sonne, N., Bredtoft, E., Andersen, F., Karsdal, M.A. and Henriksen, K. (2022). Does receptor balance matter? – Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models. Biomedicine & Pharmacotherapy. Elsevier.
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For detailed information about Cagrilintide by Stealth Labs, consult with your doctor or healthcare professional.
Larsen, A.T., Mohamed, K.E., Sonne, N., Bredtoft, E., Andersen, F., Karsdal, M.A. and Henriksen, K. (2022). Does receptor balance matter? – Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models. Biomedicine & Pharmacotherapy. Elsevier.
Larsen, A.T., Mohamed, K.E., Sonne, N., Bredtoft, E., Andersen, F., Karsdal, M.A. and Henriksen, K. (2022). Does receptor balance matter? – Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models. Biomedicine & Pharmacotherapy. Elsevier.
Larsen, A.T., Mohamed, K.E., Sonne, N., Bredtoft, E., Andersen, F., Karsdal, M.A. and Henriksen, K. (2022). Does receptor balance matter? – Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models. Biomedicine & Pharmacotherapy. Elsevier.
Home
